SCHEMBL3290733

SCHEMBL3290733

CN(C)CCNc1c2nc3ccccc3c-2n(C)c2ccccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.51
RAD52 P43351 3/20 0.51
SLC2A1 P11166 2/20 0.51
NPC1 O15118 1/20 0.51
APOBEC3A P31941 1/20 0.51
RAB9A P51151 1/20 0.51
KMT2A Q03164 1/20 0.51
APOBEC3G Q9HC16 1/20 0.51
PABPC1 P11940 1/20 0.49
EIF4H Q15056 1/20 0.49
TERT O14746 2/20 0.48
HRH3 Q9Y5N1 1/20 0.48
NCF1 P14598 2/20 0.48
TOP2A P11388 1/20 0.48
TLR9 Q9NR96 2/20 0.45
ALDH1A1 P00352 2/20 0.45
MKNK1 Q9BUB5 1/20 0.44
MKNK2 Q9HBH9 1/20 0.44
SMARCA2 P51531 1/20 0.44
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3292083 0.83 RAD52 (0.47) POLBRAD52SLC2A1NPC1APOBEC3A
SCHEMBL3298450 0.81 KAT2B (0.44) POLBRAD52SLC2A1NPC1APOBEC3A
SCHEMBL3427601 0.76 EGFR (0.43) SLC2A1TERTALDH1A1
SCHEMBL3427605 0.76 EGFR (0.43) SLC2A1TERTALDH1A1
SCHEMBL3291426 0.75 BRD4 (0.46) NPC1RAB9AKMT2AHRH3GAA
SCHEMBL3519650 0.74 CACNA2D1 (0.40) POLBRAD52SLC2A1NPC1APOBEC3A
SCHEMBL5492192 0.74 TERT (0.40) POLBRAD52SLC2A1NPC1APOBEC3A
Biscryptolepine SCHEMBL30192568 0.72 TERT (0.54) POLBNPC1RAB9AKMT2ATERT
SCHEMBL14797501 0.72 PDGFRB (0.61) POLBNPC1RAB9AKMT2ATERT
SCHEMBL3291144 0.70 TERT (0.53) POLBKMT2ATERTTOP2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100331355-A1 Substituted Quinolines for the Treatment of Cancer CRYSTAX PHARMACEUTICALS, S.L. (ES) 2010-12-30 US disclosed
US-7728000-B2 Substituted quinolines for the treatment of cancer CRYSTAX PHARMACEUTICALS (ES) 2010-06-01 US disclosed
US-20070105784-A1 Substituted quinolines for the treatment of cancer CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105784-A1 Substituted quinolines for the treatment of cancer TOP2B, NQO2, SNRPD2 POLB 599/4885RAD52 224/4885SLC2A1 1392/4885
US-20100331355-A1 Substituted Quinolines for the Treatment of Cancer TOP2B, TOP1, TOP2A POLB 607/4885RAD52 198/4885SLC2A1 1045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.